Garibaldi, 606 patient remdesivir late treatment study: 20% lower mortality [p=0.44] and 35% better improvement [p<0.0001] https://c19p.org/garibaldi
copied to clipboard
Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19
et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint)
Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality.[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
|
risk of death, 20.0% lower, HR 0.80, p = 0.44, treatment 23 of 303 (7.6%), control 45 of 303 (14.9%), adjusted per study.
|
|
risk of no improvement at day 28, 35.0% better, RR 0.65, p < 0.001, treatment 52 of 303 (17.2%), control 80 of 303 (26.4%), NNT 11, adjusted per study.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Garibaldi et al., 11/20/2020, retrospective, USA, North America, preprint, 10 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.